垂体腺苷酸环化酶激活肽致大鼠实验性偏头痛
|
摘要
目的:
通过观察wistar大鼠尾静脉注射垂体腺苷酸环化酶激活肽38(PACAP38)后的行为学变化以及三叉神经核尾核(TNC)部位c-fos蛋白的表达情况,探讨PACAP38能否作为诱导剂,诱导大鼠偏头痛发作,以制备新的可靠的实验性偏头痛大鼠模型,并初步探讨PACAP38诱导大鼠偏头痛发作的可能机制。
方法:
1.选用30只wistar大鼠(250～300g)为研究对象,将其随机分为5组,雌雄各半。空白对照组:大鼠尾静脉注射生理盐水1ml/kg;硝酸甘油模型组:大鼠尾静脉注射硝酸甘油(NTG)2μg/kg;PACAP38低剂量组:大鼠尾静脉给予3μg/kg的PACAP38;PACAP38中剂量组:大鼠尾静脉给予6μg/kg的PACAP38;PACAP38高剂量组:给予12μg/kg的PACAP38。
2.尾静脉给予不同实验试剂后即开始观察大鼠行为学变化。主要包括以下内容:①耳红:观察并记录大鼠耳红开始以及结束的时间;②挠头:观察记录大鼠挠头出现及结束的时间,采用持续时间分段计数的方法记录大鼠在尾静脉注射不同实验试剂后每一时间段中挠头的次数;③爬笼:采用持续时间分段计数的方法记录大鼠在尾静脉实验干预后每一时间段内的爬笼次数。
3.大鼠尾静脉注射不同实验试剂4h后,腹腔麻醉、灌注固定,于脑立体定位仪上,由延髓闩部向尾端切取4mm脑干标本。应用免疫组织化学技术行c-fos蛋白染色,于光学显微镜下观察c-fos蛋白表达情况。
结果:
1.行为学比较:①耳红:除空白组外,硝酸甘油组和PACAP38低、中、高三组均出现了耳红,且4组中出现与消失时间相互平行,组间比较无统计学意义(p﹥0.05)。②挠头,硝酸甘油组、PACAP38中剂量组、PACAP38高剂量组出现了挠头次数增多现象,出现及消失时间与耳红结果相似。各分段时间挠头次数统计学比较3组间无显著差异(p﹥0.05),空白组与此3组分别比较有显著差异(p﹤0.05);PACAP38低剂量组较空白组未出现明显的挠头次数增多(p﹥0.05),各分段时间挠头次数与硝酸甘油组比较有统计学意义(p﹤0.05),③爬笼:硝酸甘油组、PACAP38中剂量组、PACAP38高剂量组均较空白组出现了爬笼次数增多现象(p﹤0.05),三组间比较无统计学意义(p﹥0.05);PACAP38低剂量组与空白组比较无明显爬笼次数增多(p﹥0.05),与硝酸甘油组统计学比较有显著性差异(p﹤0.05)。
2. c-fos蛋白表达:光学显微镜下可见切片背景为淡黄色或无色,阳性细胞呈黄褐色,多为圆形或卵圆形,以核染为主,易与背景区分,主要分布在三叉神经脊束核尾核(TNC)。硝酸甘油组、PACAP38中剂量组、PACAP38高剂量组大鼠脑干标本c-fos免疫阳性细胞较空白对照组明显增加(p﹤0.05),三组间比较无明显差异(p﹥0.05);PACAP38低剂量组脑干标本c-fos免疫阳性细胞较空白组无明显增加(p﹥0.05),与硝酸甘油组比较有显著性差异(p﹤0.05)。结论:
PACAP38可以诱导大鼠偏头痛发作,可能成为新的偏头痛大鼠模型的诱导剂制备偏头痛动物实验模型,并利于更深入的研究偏头痛发病机制及新的防治药物的开发。
Objective:
Through the observation of the behavioral changes and c-fos expression with trigeminal nucleus tail nuclear (TNC) of the rat following intravenous Pituitary adenylate cyclase activating peptide-38 (PACAP38),to discusses whether PACAP38 can induce migraine attacks in rat to build a new reliable experimental animal model of migraine, and discusses the possible mechanism of PACAP38 induce migraine attacks.
Methods:
1. 30 experimental migraine rat weighted 200~250g were randomly divided into five groups: sham group(group1),NTG group(group2), PACAP38 LD group (group3), PACAP38 MD group(group4),PACAP38 HD group(group5),1ml/kg physiological saline infusion to sham group;2μg/kg glyceryltrinitrate infusion to NTG group;3μg/kg PACAP38 infusion to PACAP38 LD group;6μg/kg PACAP38 infusion to PACAP38 HD group;12μg/kg PACAP38 infusion to PACAP38 HD group.
2. To appraise behavior changes of the rat.The time of turning red of ears and frequency of scratching head and climbing hutch were observed every 30 minuts after infusion and comparae with eachother.
3.4h after infusion,paralyzerat,rat were paralyzed and perfuse to fix,which the brainstem were removed and post-fixed.The expression of c-fos immuno-reactivities was detected with immunohistohistochemical method.
Results:
1.Ethology comparison:①red ears: beside group1,group2,3,4,5 were appeared reddish two ears. There is no statistical difference in the time of turning red of ears in group2,3,4,5.(p﹥0.05).②scratching head:group2,4,5 appeared a phenomenon of scratching head.There is no statistical difference in the frequency of scratching head in group2,4,5.Compared with group1,the frequency of scratching head was significantly increased(p﹤0.05). There is no statistical difference in the frequency of scratching head between group1,3,and compared with group2 , the frequency of scratching head was significantly lower(p﹤0.05).③climbing hutch: group2,4,5 appeared a phenomenon of climbing hutch.There is no statistical difference in the frequency of climbing hutch in group2,4,5.Compared with group1,the frequency of climbing hutch was significantly increased(p﹤0.05). There is no statistical difference in the frequency of climbing hutch between group1,3.and compared with group2 ,the frequency of climbing hutch was significantly lower(p﹤0.05).
2. In microscope,the cell was tasteless in background, the positive cell was yellow in TNC. The positive cell in group2,4,5 was obviously increased comrared with group1(p﹤0.05),and no signigicant difference between eachother(p﹥0.05). Compared with group1,there is no obviously increased in group3(p﹥0.05).
Conclusion:
PACAP38 can induce rats migraine attacks,and can be used as inducer to build a new reliable experimental animal model that can mimic the migraine attacks,and can be used in the basic research on the mechanism,therapeuical drug and other approaches of migraine.
通过观察wistar大鼠尾静脉注射垂体腺苷酸环化酶激活肽38(PACAP38)后的行为学变化以及三叉神经核尾核(TNC)部位c-fos蛋白的表达情况,探讨PACAP38能否作为诱导剂,诱导大鼠偏头痛发作,以制备新的可靠的实验性偏头痛大鼠模型,并初步探讨PACAP38诱导大鼠偏头痛发作的可能机制。
方法:
1.选用30只wistar大鼠(250～300g)为研究对象,将其随机分为5组,雌雄各半。空白对照组:大鼠尾静脉注射生理盐水1ml/kg;硝酸甘油模型组:大鼠尾静脉注射硝酸甘油(NTG)2μg/kg;PACAP38低剂量组:大鼠尾静脉给予3μg/kg的PACAP38;PACAP38中剂量组:大鼠尾静脉给予6μg/kg的PACAP38;PACAP38高剂量组:给予12μg/kg的PACAP38。
2.尾静脉给予不同实验试剂后即开始观察大鼠行为学变化。主要包括以下内容:①耳红:观察并记录大鼠耳红开始以及结束的时间;②挠头:观察记录大鼠挠头出现及结束的时间,采用持续时间分段计数的方法记录大鼠在尾静脉注射不同实验试剂后每一时间段中挠头的次数;③爬笼:采用持续时间分段计数的方法记录大鼠在尾静脉实验干预后每一时间段内的爬笼次数。
3.大鼠尾静脉注射不同实验试剂4h后,腹腔麻醉、灌注固定,于脑立体定位仪上,由延髓闩部向尾端切取4mm脑干标本。应用免疫组织化学技术行c-fos蛋白染色,于光学显微镜下观察c-fos蛋白表达情况。
结果:
1.行为学比较:①耳红:除空白组外,硝酸甘油组和PACAP38低、中、高三组均出现了耳红,且4组中出现与消失时间相互平行,组间比较无统计学意义(p﹥0.05)。②挠头,硝酸甘油组、PACAP38中剂量组、PACAP38高剂量组出现了挠头次数增多现象,出现及消失时间与耳红结果相似。各分段时间挠头次数统计学比较3组间无显著差异(p﹥0.05),空白组与此3组分别比较有显著差异(p﹤0.05);PACAP38低剂量组较空白组未出现明显的挠头次数增多(p﹥0.05),各分段时间挠头次数与硝酸甘油组比较有统计学意义(p﹤0.05),③爬笼:硝酸甘油组、PACAP38中剂量组、PACAP38高剂量组均较空白组出现了爬笼次数增多现象(p﹤0.05),三组间比较无统计学意义(p﹥0.05);PACAP38低剂量组与空白组比较无明显爬笼次数增多(p﹥0.05),与硝酸甘油组统计学比较有显著性差异(p﹤0.05)。
2. c-fos蛋白表达:光学显微镜下可见切片背景为淡黄色或无色,阳性细胞呈黄褐色,多为圆形或卵圆形,以核染为主,易与背景区分,主要分布在三叉神经脊束核尾核(TNC)。硝酸甘油组、PACAP38中剂量组、PACAP38高剂量组大鼠脑干标本c-fos免疫阳性细胞较空白对照组明显增加(p﹤0.05),三组间比较无明显差异(p﹥0.05);PACAP38低剂量组脑干标本c-fos免疫阳性细胞较空白组无明显增加(p﹥0.05),与硝酸甘油组比较有显著性差异(p﹤0.05)。结论:
PACAP38可以诱导大鼠偏头痛发作,可能成为新的偏头痛大鼠模型的诱导剂制备偏头痛动物实验模型,并利于更深入的研究偏头痛发病机制及新的防治药物的开发。
Objective:
Through the observation of the behavioral changes and c-fos expression with trigeminal nucleus tail nuclear (TNC) of the rat following intravenous Pituitary adenylate cyclase activating peptide-38 (PACAP38),to discusses whether PACAP38 can induce migraine attacks in rat to build a new reliable experimental animal model of migraine, and discusses the possible mechanism of PACAP38 induce migraine attacks.
Methods:
1. 30 experimental migraine rat weighted 200~250g were randomly divided into five groups: sham group(group1),NTG group(group2), PACAP38 LD group (group3), PACAP38 MD group(group4),PACAP38 HD group(group5),1ml/kg physiological saline infusion to sham group;2μg/kg glyceryltrinitrate infusion to NTG group;3μg/kg PACAP38 infusion to PACAP38 LD group;6μg/kg PACAP38 infusion to PACAP38 HD group;12μg/kg PACAP38 infusion to PACAP38 HD group.
2. To appraise behavior changes of the rat.The time of turning red of ears and frequency of scratching head and climbing hutch were observed every 30 minuts after infusion and comparae with eachother.
3.4h after infusion,paralyzerat,rat were paralyzed and perfuse to fix,which the brainstem were removed and post-fixed.The expression of c-fos immuno-reactivities was detected with immunohistohistochemical method.
Results:
1.Ethology comparison:①red ears: beside group1,group2,3,4,5 were appeared reddish two ears. There is no statistical difference in the time of turning red of ears in group2,3,4,5.(p﹥0.05).②scratching head:group2,4,5 appeared a phenomenon of scratching head.There is no statistical difference in the frequency of scratching head in group2,4,5.Compared with group1,the frequency of scratching head was significantly increased(p﹤0.05). There is no statistical difference in the frequency of scratching head between group1,3,and compared with group2 , the frequency of scratching head was significantly lower(p﹤0.05).③climbing hutch: group2,4,5 appeared a phenomenon of climbing hutch.There is no statistical difference in the frequency of climbing hutch in group2,4,5.Compared with group1,the frequency of climbing hutch was significantly increased(p﹤0.05). There is no statistical difference in the frequency of climbing hutch between group1,3.and compared with group2 ,the frequency of climbing hutch was significantly lower(p﹤0.05).
2. In microscope,the cell was tasteless in background, the positive cell was yellow in TNC. The positive cell in group2,4,5 was obviously increased comrared with group1(p﹤0.05),and no signigicant difference between eachother(p﹥0.05). Compared with group1,there is no obviously increased in group3(p﹥0.05).
Conclusion:
PACAP38 can induce rats migraine attacks,and can be used as inducer to build a new reliable experimental animal model that can mimic the migraine attacks,and can be used in the basic research on the mechanism,therapeuical drug and other approaches of migraine.
引文
[1] Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343–9.
[2]郭述苏,薛广波.中国偏头痛流行病学初步调查[J].中华流行病学杂志,1993,14(2): 102.
[3] Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia2007 ; 27(5):394–402.
[4]Nadone R,Tezzon F.Short latency teigemino-ternocleidomastoid response in patients with migraine[J].J Neurol,2003,250(6):725-732
[5] Henrik Winther Schytz, Steffen Birk, Troels Wienecke;et al. PACAP38 induces migraine-like attacks in patients with migraine without aura.[J] Brain 2009: 132; 16–25 16.
[6]赵志奇主编.疼痛及其脊髓机理[M].上海:上海教育出版社,2000,10:39-40
[7] Satoh S,ToshimaY, Ikegaki I,et al.Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils. Res,2007,1128(1):175一180.
[8] Shin HK, Salomone S, Potts EM,et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.J Cereb Blood Flow Metab,2007,27(5):998-1009.
[9] Satoh S, Toshima Y, Hitomi A, et al. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res,2008,1193:102-108.
[10] Afridi SK, Giffin NJ, Kaube H. A Positron Emission Tomographic Study in Spontaneous Migraine. Arch Neurol, 2005,62(8):1270-1275.
[11]章正祥等.从临床到基础:硝酸甘油实验性偏头痛大鼠模型信度和效度评价[J].中国实验动物学报.2009,8(4):311-313.
[12]付先军,宋旭霞,周永红,等.硝酸甘油型实验性偏头痛大鼠模型行为症状学评价[J].中华神经医学杂志,2005,4(5):449-451.
[13]Hunt sp,Pini A.Induction of c-fos-like protein in spinal cord neurons following sensory stimulation.[J].Nature.1987,328(6131):632-4.
[14] Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP) : discovery and current status of research. RegulPept, 1992, 37∶287-303.
[15]宋爱丽.浅析偏头痛的成因及防治措施[J].中国实用医药.2008,11(3):129-130.
[16] Uddman R, Goadsby PJ, Jansen I, Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 1993,13: 291–7.
[17] Takahashi K, Tosune K, MurakamiO ,etal. Potuitary adenylate cyclase activat ing polypeptide (PACAP)-like immunoreactivityin human hypothalamus: Colocalitarion with arginine vasopressin.regul pwpt,1994,50:267～~275. sop ressin. Regul Pep t, 1994, 50∶267～275.
[18] Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999,76: 176–83.
[19] Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002, 22: 11–6.
[20] Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 1999, 826: 193–9.
[21] Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998,50:265–270.
[22] Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009,132:16–25.
[23] Odum L, Petersen LJ, Skov PS, Ebskov LB. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 1998,47:488–492.
[24] Schytz HW, Holst H, Arendt-Nielsen L, Olesen L, Ashina M. Cutaneous nociception and neurogenic inflammation evoked by VIP and PACAP38: a human experimental study. Cephalalgia 2009,29(12):1358 (abstract LBPO08).
[25] Tamaki M,Norihito S. Pituitary Adenylate Cyclase-Activating Polypeptide Is Required forthe Development of Spinal Sensitization and Induction of Neuropathic Pain. The Journal of Neuroscience 2004 ,24(33):7283–7291. 7283.
[26] Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993,267:690–696.
[27]Ingram SL, Williams JT. Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 1996,492: 97–106.
[28] Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998,79: 964–82.
[29] Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 2006,26:1304–1309.
[30] Ho TW, Mannix LK, Fan X, et al.; MK-0974 Protocol 004 StudyGroup. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008,70:1304–1312.
[1] Miyata A ,Arimura A ,Dahl RR,et al. Isolation of a novel 38 residuehypothalamic polypeptide which stimulate adenylate cyclase in pituitary cells.Biochem Biophys Res Commun.1989, 164(1) :567-74
[2] ArimuraA, ShiodaS.Pituitaryadenylatecyclaseactivating polypeptide(PACAP) anditsreceptors: neuroendocrineand endocrineinteraction. FrontiersinNeuroendocrine. l995, l6(1):53~88
[3] Ghatei MA ,Takahashi K, Suzuki Y,et al. Distribution molecular characterization of pituitary adenylate cyclase activating polypeptde and its precursor encoding messenger RNA in human and rat tissue. J Endocrinol. 1993,136(1):159~166.
[4] Kivipelto L ,Abood A ,Arimura A ,et al. The distribution of pituritary adenylate cyclase activating polypeptide - like immunoreactiv2ity is distincted from helodermin and helospectin - like immunoreactivities in the rat brain. J Chem Neuroanat .1992 ,5 :851
[5] Koves K, A rimura A , Somogyvariigh A , et al. Immunoh istochem ical demonst rat ion of a novel hypothalamic peptide, petuitary adenylate cyclase activat ing polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in rat forebrain. Neuroendocrinology, 1991, 54: 159~169.
[6]唐胜球,董晓英等.垂体腺苷酸环化酶激活肽的分布及其生物学功能.生命科学. 2004,16(2):109-113.
[7]林毅勇.垂体腺苷酸环化酶激活肽及其神经营养作用.国外医学神经病学神经外科学分册.2000,27(6):299-302.
[8] Mori H,Nakamachi T,Ohtaki H,et al. Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-Induce cardiomyopathy in mice.Circulation Journal .2010,74(6):1183-90.
[9] Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K.The effect of pituitary adenylate cyclase activating polypeptide oncultured rat cardiocytes as a cardioprotective factor. Regul Pept.2002,109: 107– 113
[10] Yang S, Yang J, Yang Z, Chen P, Fraser A, Zhang W, et al. Pituitaryadenylate cyclase-activating polypeptide (PACAP)38 andPACAP4-6 are neuroprotective through inhibition of NADPHoxidase: Potent regulators of microglia-mediated oxidative stress.J Pharmacol ExpTher. 2006,319: 595– 603.
[11] Henrik W, Steffen B,Troels,W,Christina K,et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009,132:16–25.
[12] S Gupta,DK Bhatt, et al..Improvement of the closed cranialwindow model in rats by intracarotid infusion of signalling molecules implicated in migraine. International Headache Society .2009:30(1) 27–36.
[13] T. K. Monaghan,T. K. Monaghan,et al. PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. JOURNAL OF NEUROCHEMISTRY .2008:104 74–88.
[14] Sufen Y,Jun Y,et al. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 38 and PACAP4–6 Are Neuroprotective through Inhibition of NADPH Oxidase: Potent Regulators of Microglia-Mediated Oxidative Stress. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2006:319:595–603.
[15] D. B. Cameron. E Raoult. Role of PACAP in Controlling Granule Cell Migration. Cerebellum .2009,8:433–440.
[16] Mclaughlin JT,Ai W,Sinclair NF,et al. PACAP and gastrin regulate the histidine decarboxylase promoter via distinct mechanisms. Am J Physiol Gastrointest Liver Physiol .2004, 286(1):G51-9.
[17]Pena F.PACAP Modulates the respiratory rhythm generated in the brainstem slice preparation.Adv Exp Med Biol.2010,669:119-22.
[18] Yossan-Var Tan,Catalina Abad,et al. Pituitary adenylylcyclase- activating polypeptide is anintrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis.PNAS.2009:1012-1017.
[19] Kawaquchi C,Isojima Y,Shintani N,et al. PACAP-deficient mice exhibit light Parameter– Dependent abnormalities on nonvisual photoreception and Early activity onset.PLos One. 2010 ,5(2):e9286.
[20] Ster J,de Bock F,Bertaso F,et al. Epac mediates PACAP-dependent long-term depression in the hippocampus. J Physiol .2009,587(pt1):101-13.
[21] YU Rong-Jie,ZHANG Ling,et al. In vivo anti-obesity effect of the agonist for receptor VPAC1. Acta Physiologica Sinica, December 25, 2008, 60 (6): 751-758.
[22] Hashimoto R,Hashimoto H,Shintani,et al.Possible association between the pituitary adenyl- atecyclase–activeting polypeptide (PACAP) gene and major depressive disorder. Neuroscience Letters .2010,468(3):300-2.
[2]郭述苏,薛广波.中国偏头痛流行病学初步调查[J].中华流行病学杂志,1993,14(2): 102.
[3] Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia2007 ; 27(5):394–402.
[4]Nadone R,Tezzon F.Short latency teigemino-ternocleidomastoid response in patients with migraine[J].J Neurol,2003,250(6):725-732
[5] Henrik Winther Schytz, Steffen Birk, Troels Wienecke;et al. PACAP38 induces migraine-like attacks in patients with migraine without aura.[J] Brain 2009: 132; 16–25 16.
[6]赵志奇主编.疼痛及其脊髓机理[M].上海:上海教育出版社,2000,10:39-40
[7] Satoh S,ToshimaY, Ikegaki I,et al.Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils. Res,2007,1128(1):175一180.
[8] Shin HK, Salomone S, Potts EM,et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.J Cereb Blood Flow Metab,2007,27(5):998-1009.
[9] Satoh S, Toshima Y, Hitomi A, et al. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res,2008,1193:102-108.
[10] Afridi SK, Giffin NJ, Kaube H. A Positron Emission Tomographic Study in Spontaneous Migraine. Arch Neurol, 2005,62(8):1270-1275.
[11]章正祥等.从临床到基础:硝酸甘油实验性偏头痛大鼠模型信度和效度评价[J].中国实验动物学报.2009,8(4):311-313.
[12]付先军,宋旭霞,周永红,等.硝酸甘油型实验性偏头痛大鼠模型行为症状学评价[J].中华神经医学杂志,2005,4(5):449-451.
[13]Hunt sp,Pini A.Induction of c-fos-like protein in spinal cord neurons following sensory stimulation.[J].Nature.1987,328(6131):632-4.
[14] Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP) : discovery and current status of research. RegulPept, 1992, 37∶287-303.
[15]宋爱丽.浅析偏头痛的成因及防治措施[J].中国实用医药.2008,11(3):129-130.
[16] Uddman R, Goadsby PJ, Jansen I, Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 1993,13: 291–7.
[17] Takahashi K, Tosune K, MurakamiO ,etal. Potuitary adenylate cyclase activat ing polypeptide (PACAP)-like immunoreactivityin human hypothalamus: Colocalitarion with arginine vasopressin.regul pwpt,1994,50:267～~275. sop ressin. Regul Pep t, 1994, 50∶267～275.
[18] Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999,76: 176–83.
[19] Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002, 22: 11–6.
[20] Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 1999, 826: 193–9.
[21] Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998,50:265–270.
[22] Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009,132:16–25.
[23] Odum L, Petersen LJ, Skov PS, Ebskov LB. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 1998,47:488–492.
[24] Schytz HW, Holst H, Arendt-Nielsen L, Olesen L, Ashina M. Cutaneous nociception and neurogenic inflammation evoked by VIP and PACAP38: a human experimental study. Cephalalgia 2009,29(12):1358 (abstract LBPO08).
[25] Tamaki M,Norihito S. Pituitary Adenylate Cyclase-Activating Polypeptide Is Required forthe Development of Spinal Sensitization and Induction of Neuropathic Pain. The Journal of Neuroscience 2004 ,24(33):7283–7291. 7283.
[26] Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993,267:690–696.
[27]Ingram SL, Williams JT. Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 1996,492: 97–106.
[28] Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998,79: 964–82.
[29] Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 2006,26:1304–1309.
[30] Ho TW, Mannix LK, Fan X, et al.; MK-0974 Protocol 004 StudyGroup. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008,70:1304–1312.
[1] Miyata A ,Arimura A ,Dahl RR,et al. Isolation of a novel 38 residuehypothalamic polypeptide which stimulate adenylate cyclase in pituitary cells.Biochem Biophys Res Commun.1989, 164(1) :567-74
[2] ArimuraA, ShiodaS.Pituitaryadenylatecyclaseactivating polypeptide(PACAP) anditsreceptors: neuroendocrineand endocrineinteraction. FrontiersinNeuroendocrine. l995, l6(1):53~88
[3] Ghatei MA ,Takahashi K, Suzuki Y,et al. Distribution molecular characterization of pituitary adenylate cyclase activating polypeptde and its precursor encoding messenger RNA in human and rat tissue. J Endocrinol. 1993,136(1):159~166.
[4] Kivipelto L ,Abood A ,Arimura A ,et al. The distribution of pituritary adenylate cyclase activating polypeptide - like immunoreactiv2ity is distincted from helodermin and helospectin - like immunoreactivities in the rat brain. J Chem Neuroanat .1992 ,5 :851
[5] Koves K, A rimura A , Somogyvariigh A , et al. Immunoh istochem ical demonst rat ion of a novel hypothalamic peptide, petuitary adenylate cyclase activat ing polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in rat forebrain. Neuroendocrinology, 1991, 54: 159~169.
[6]唐胜球,董晓英等.垂体腺苷酸环化酶激活肽的分布及其生物学功能.生命科学. 2004,16(2):109-113.
[7]林毅勇.垂体腺苷酸环化酶激活肽及其神经营养作用.国外医学神经病学神经外科学分册.2000,27(6):299-302.
[8] Mori H,Nakamachi T,Ohtaki H,et al. Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-Induce cardiomyopathy in mice.Circulation Journal .2010,74(6):1183-90.
[9] Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K.The effect of pituitary adenylate cyclase activating polypeptide oncultured rat cardiocytes as a cardioprotective factor. Regul Pept.2002,109: 107– 113
[10] Yang S, Yang J, Yang Z, Chen P, Fraser A, Zhang W, et al. Pituitaryadenylate cyclase-activating polypeptide (PACAP)38 andPACAP4-6 are neuroprotective through inhibition of NADPHoxidase: Potent regulators of microglia-mediated oxidative stress.J Pharmacol ExpTher. 2006,319: 595– 603.
[11] Henrik W, Steffen B,Troels,W,Christina K,et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009,132:16–25.
[12] S Gupta,DK Bhatt, et al..Improvement of the closed cranialwindow model in rats by intracarotid infusion of signalling molecules implicated in migraine. International Headache Society .2009:30(1) 27–36.
[13] T. K. Monaghan,T. K. Monaghan,et al. PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. JOURNAL OF NEUROCHEMISTRY .2008:104 74–88.
[14] Sufen Y,Jun Y,et al. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 38 and PACAP4–6 Are Neuroprotective through Inhibition of NADPH Oxidase: Potent Regulators of Microglia-Mediated Oxidative Stress. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2006:319:595–603.
[15] D. B. Cameron. E Raoult. Role of PACAP in Controlling Granule Cell Migration. Cerebellum .2009,8:433–440.
[16] Mclaughlin JT,Ai W,Sinclair NF,et al. PACAP and gastrin regulate the histidine decarboxylase promoter via distinct mechanisms. Am J Physiol Gastrointest Liver Physiol .2004, 286(1):G51-9.
[17]Pena F.PACAP Modulates the respiratory rhythm generated in the brainstem slice preparation.Adv Exp Med Biol.2010,669:119-22.
[18] Yossan-Var Tan,Catalina Abad,et al. Pituitary adenylylcyclase- activating polypeptide is anintrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis.PNAS.2009:1012-1017.
[19] Kawaquchi C,Isojima Y,Shintani N,et al. PACAP-deficient mice exhibit light Parameter– Dependent abnormalities on nonvisual photoreception and Early activity onset.PLos One. 2010 ,5(2):e9286.
[20] Ster J,de Bock F,Bertaso F,et al. Epac mediates PACAP-dependent long-term depression in the hippocampus. J Physiol .2009,587(pt1):101-13.
[21] YU Rong-Jie,ZHANG Ling,et al. In vivo anti-obesity effect of the agonist for receptor VPAC1. Acta Physiologica Sinica, December 25, 2008, 60 (6): 751-758.
[22] Hashimoto R,Hashimoto H,Shintani,et al.Possible association between the pituitary adenyl- atecyclase–activeting polypeptide (PACAP) gene and major depressive disorder. Neuroscience Letters .2010,468(3):300-2.